For many pharmaceutical companies, reshoring oral solid dosage (OSD) manufacturing is becoming an operational priority. Between evolving trade policies, geopolitical uncertainty, regulatory risk, and an increasing pressure to strengthen supply chains, many sponsors are reevaluating where their products are manufactured.
Simply moving production across your supply chain map to the United States, therefore, isn't the objective. The real goal is building a more resilient manufacturing strategy, and that requires choosing the right domestic manufacturing partner.
Below are three critical questions that will help guide your decision-making process.
1. Will this move reduce our supply chain risk?
A U.S.-based manufacturing site should reduce exposure to the factors that create disruption in the first place, including:
- Tariffs and changing trade policies
- International shipping delays
- Geopolitical instability
- Complex global logistics
It goes without saying that the tariff landscape is particularly fluid at this moment. When evaluating potential partners, ask how they help customers maintain continuity if market conditions change unexpectedly.
Domestic manufacturing can address this risk, while also helping shorten supply chains, simplify transportation, and reduce dependence on overseas production. The result is often greater predictability.
2. Will working with this manufacturer improve regulatory responsiveness?
Regulatory collaboration often becomes easier when manufacturing is closer to home. A U.S.-based contract development and manufacturing organization (CDMO) can make it easier to coordinate FDA interactions and on-site visits, and it can also simplify and accelerate the resolution of any manufacturing questions.
Proximity also allows cross-functional teams to come together during technology transfer or commercial production.
While quality systems ultimately matter more than geography, proximity can improve communication and speed up decision-making throughout a product's lifecycle.
For sponsors managing complex commercial products, those efficiencies can translate into fewer delays and stronger working relationships.
3. Can a partner adapt as our business changes?
Demand forecasts shift. Product portfolios expand. Market conditions evolve. Accordingly, today's manufacturing decisions need to support tomorrow's commercial realities. Re-shoring your OSD manufacturing in this environment requires a strong domestic manufacturing partner that can provide crucial flexibility.
That includes inventory strategies that support changing customer demand, and commercial manufacturing capacity that can scale with growth. When operational issues arise, rapid response times can reduce systemic pressures. Last, the partner must provide long-term support, throughout a product’s lifecycle.
The right contract manufacturer has the capacity you need today, with the ability to continue supporting your business as your needs change over the unpredictable years ahead.
Reshoring Is About More Than Location
Choosing to manufacture in the United States complements a long-term strategy for building a supply chain that is more resilient, responsive, and prepared for uncertainty.
As pharmaceutical companies continue to evaluate their manufacturing strategies, the strongest partners will be those that offer operational expertise, regulatory experience, and the flexibility to support commercial success over the long term. A partner that offers domestic production provides added strength.
Ready to explore the advantages of U.S. manufacturing with a full-service CDMO offering end-to-end pharma solutions? Connect with UPM Pharmaceuticals and learn more about how domestic manufacturing can help strengthen your OSD supply chain.